Yukinori Endo
Overview
Explore the profile of Yukinori Endo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng H, Endo Y, Wu W
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001429
The mechanisms of mAb-induced ADCC have been well established. However, the ADCC bioassays used to quantify mAb-induced ADCC require continued development/refinement to properly assess and compare the potency of newly...
2.
Endo Y, Winarski K, Sajib M, Ju A, Wu W
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511454
Atezolizumab is an immune checkpoint inhibitor (ICI) targeting PD-L1 for treatment of solid malignancies. Immune checkpoints control the immune tolerance, and the adverse events such as hepatotoxicity induced by ICIs...
3.
Endo Y, Hickerson B, Ilyushina N, Mohan N, Peng H, Takeda K, et al.
J Virus Erad
. 2022 Dec;
8(4):100307.
PMID: 36514715
Because of rapid emergence and circulation of the SARS-CoV-2 variants, especially Omicron which shows increased transmissibility and resistant to antibodies, there is an urgent need to develop novel therapeutic drugs...
4.
Mohan N, Agrawal A, Shen Y, Winarski K, Endo Y, Dokmanovic M, et al.
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890277
We generated two IgG1-like bispecific antibodies (BsAbs) with different molecular formats, symmetrical DVD-Ig and asymmetrical knob-in-hole (KIH), targeting the same antigens, EGFR and PD-L1 (designated as anti-EGFR/PD-L1). We performed the...
5.
Endo Y, Wu W
Cancers (Basel)
. 2021 Jun;
13(10).
PMID: 34066157
To explore if the tumor microenvironment contributes to the primary resistance of HER2-positive breast cancer cells to T-DM1, we examined whether Matrigel, a basement membrane matrix that provides a three-dimensional...
6.
Endo Y, Mohan N, Dokmanovic M, Wu W
Antib Ther
. 2021 May;
4(1):55-59.
PMID: 33937626
In order to improve the safety of novel therapeutic drugs, better understanding of the mechanisms of action is important. Ado-trastuzumab emtansine (also known as T-DM1) is an antibody-drug conjugate (ADC)...
7.
Mohan N, Luo X, Shen Y, Olson Z, Agrawal A, Endo Y, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33804477
Both EGFR and VEGFR2 frequently overexpress in TNBC and cooperate with each other in autocrine and paracrine manner to enhance tumor growth and angiogenesis. Therapeutic mAbs targeting EGFR (cetuximab) and...
8.
Endo Y, Lyon S, Shen Y, Mohan N, Wu W
Sci Rep
. 2019 Nov;
9(1):16383.
PMID: 31704984
We recently reported that T-DM1-resistant JIMT1 (T-DM1R-JIMT1) cells exhibited high invasive activity via EGFR and integrin cooperated pathways and gained cross-resistance to doxorubicin. Here, we show that EGFR positively coordinates...
9.
Liu F, Endo Y, Romantseva T, Wu W, Akue A, Shen R, et al.
Sci Signal
. 2019 Oct;
12(602).
PMID: 31594856
Vaccine adjuvants containing analogs of microbial products activate pattern recognition receptors (PRRs) on antigen-presenting cells, including monocytes and macrophages, which can cause prostaglandin E (PGE) release and consequently undesired inflammatory...
10.
Mohan N, Hosain S, Zhao J, Shen Y, Luo X, Jiang J, et al.
Oncoimmunology
. 2019 Aug;
8(9):e1624128.
PMID: 31428520
Immune check point inhibitors targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1) have shown clinical success in treatment of human malignancies. Triple negative breast cancer (TNBC), which is...